Dr. Chris Leptak of the FDA’s Center for Drug Evaluation and Research discusses the three primary sources for biomarker evidence use by FDA to inform regulatory decisions – scientific community consensus, drug-specific development and approval process, and CDER’s Biomarker Qualification Program. No matter which pathway the drug developer selects, consulting with the FDA is a critical step to achieve success.